Cite
HARVARD Citation
Sticherling, M. et al. (2017). Secukinumab is superior to fumaric acid esters in treating patients with moderate‐to‐severe plaque psoriasis who are naive to systemic treatments: results from the randomized controlled PRIME trial. British journal of dermatology. pp. 1024-1032. [Online].